EXPRESSION IN HAEMATOLOGICAL MALIGNANCIES : RESPONSE TO ALKYLATING AGENT IN THE COMET ASSAY

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Study of p53 in elderly patients with myelodysplastic syndromes by immunohistochemistry and DNA analysis.

  1999influential reference
• p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.

  1998cited by this paper
• Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.

  1998influential reference
• Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas.

  1997cited by this paper
• p53 gene mutations in multiple myeloma.

  1997influential reference
• Bcl‐2, Bax and p53 expression in B‐CLL in relation to in vitro survival and clinical progression

  1996cited by this paper
• p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas.

  1996influential reference
• Absence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes.

  1995cited by this paper
• p53 mutation in the myelodysplastic syndromes

  1995cited by this paper
• TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities.

  1995cited by this paper
• p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32).

  1995influential reference
• p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.

  1994influential reference
• Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes.

  1994cited by this paper
• p53 status and the efficacy of cancer therapy in vivo.

  1994influential reference
• p53 in hematologic malignancies.

  1994influential reference
• Clonal expansion of p53 mutant cells in leukemia progression in vitro.

  1994influential reference
• Cell cycle control and cancer chemotherapy

  1994influential reference
• Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.

  1994influential reference
• Clinical implications of the p53 tumor-suppressor gene.

  1993cited by this paper
• p53 mutation is associated with progression in follicular lymphomas.

  1993cited by this paper
• Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines.

  1993influential reference
• Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia.

  1993cited by this paper
• Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes.

  1993cited by this paper
• High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells.

  1993influential reference
• p53 as an independent prognostic marker in lymph node-negative breast cancer patients.

  1993cited by this paper
• Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood.

  1993cited by this paper
• p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes.

  1993cited by this paper
• p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.

  1993cited by this paper
• Sporadic mutations of the p53 gene in multiple myeloma and no evidence for germline mutations in three familial multiple myeloma pedigrees.

  1993influential reference
• p53 mutations are associated with histologic transformation of follicular lymphoma.

  1993cited by this paper
• Detection of p53 mutations using nonradioactive SSCP analysis: p53 is not frequently mutated in myelodysplastic syndromes (MDS)

  1993cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy.

  1993cited by this paper
• p53 expression and prognosis in gastric carcinoma

  1992cited by this paper
• Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases.

  1992cited by this paper
• Mutations of p53 gene and their relation to disease progression in B-cell lymphoma.

  1992cited by this paper
• p53 and RAS gene mutations in multiple myeloma.

  1992cited by this paper
• Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

  1992cited by this paper
• Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p.

  1992influential reference
• Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation.

  1992cited by this paper
• P53 protein expression in lymphomas and reactive lymphoid tissue

  1992cited by this paper
• Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis.

  1992influential reference
• Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

  1992influential reference
• Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia.

  1992cited by this paper
• Rare occurrence of P53 gene mutations in multiple myeloma

  1992cited by this paper
• p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

  1991cited by this paper
• Mutations in the p53 gene in myelodysplastic syndromes.

  1991cited by this paper
• Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis.

  1991influential reference
• Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas.

  1991cited by this paper
• Chromosome 17p and p53 changes in lymphoma

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-beta-D-arabinofuranosylcytosine.

  1991influential reference
• Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia.

  1990cited by this paper
• Blood.

  1989cited by this paper
• A simple technique for quantitation of low levels of DNA damage in individual cells.

  1988cited by this paper
• Localization of gene for human p53 tumour antigen to band 17p13

  1986cited by this paper

• No citing papers are available for this paper.